The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Open accessAbstract
Key Points: Lenalidomide-bortezomib-dexamethasone resulted in partial response or better in nearly two-thirds of relapsed/refractory myeloma patients. The regimen had substantial activity despite high rates of prior bortezomib/thalidomide and regardless of poor prognostic characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Self-citationMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Self-citationArnulf, B., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., van de Velde, H., Feng, H., Cakana, A., Deraedt, W., & Moreau, P. (2012) · Haematologica · doi:10.3324/haematol.2012.067793 · Cited by 127
Cited by
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Chen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Drugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
The proteasome and proteasome inhibitors in multiple myeloma
Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 340
Self-citation
Metadata
- Authors
- Richardson, P. G., Xie, W., Jagannath, S., Jakubowiak, A., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Munshi, N. C., Mazumder, A., Vesole, D. H., Kaufman, J. L., Colson, K., McKenney, M., Lunde, L. E., Feather, J., Maglio, M. E., Warren, D., Francis, D., Hideshima, T., Knight, R., Esseltine, D.-L., Mitsiades, C. S., Weller, E., & Anderson, K. C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-03-06
- Volume
- 123
- Issue
- 10
- Pages
- 1461-1469
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1999964913
- Cited by
- 182
- References
- 5
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. https://app.cochat.ai/papers/10.1182/blood-2013-07-517276
- The paper
- Richardson, P. G., Xie, W., Jagannath, S., Jakubowiak, A., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Munshi, N. C., Mazumder, A., Vesole, D. H., Kaufman, J. L., Colson, K., McKenney, M., Lunde, L. E., Feather, J., Maglio, M. E., Warren, D., . . . Anderson, K. C. (2014). A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. https://doi.org/10.1182/blood-2013-07-517276
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.